BioMark Recognizes and Supports the Lung Cancer Awareness Month
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it recognizes and wanted to raise awareness of the challenges that come from a diagnosis of lung cancer. There are fundamental strides being made in both the early diagnosis and more effective therapeutic intervention that will...
2021-11-10 8:30 AM EST
Diagnostic and Therapeutic Benefits of BioMark's Cancer Marker Featured in Two Poster Presentations at the Canadian Cancer Research Conference
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that the diagnostic and therapeutic capabilities of its SSAT cancer marker will be featured in virtual posted presentation at the sixth biennial Canadian Cancer Research Conference to be held virtually from Nov 8-11, 2021. Investigators,...
2021-11-08 8:30 AM EST
Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that it will hold a virtual stand at the III annual Congress of the International Society of Liquid Biopsy to showcase its innovative technology to a key audience with compelling data from previous studies that demonstrates the ability of...
2021-10-18 8:30 AM EDT
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen With or Without Immunotherapy. Since immunotherapy is now standard of care for lung cancer, BioMark...
2021-06-29 8:30 AM EDT
BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") received funding to develop an early-stage lung cancer screening assay using BioMark's proprietary liquid biopsy platform. The total sponsored research grant is about $825,000 and a major portion of the funding is being provided by the Consortium for...
2021-06-01 8:30 AM EDT
BioMark reçoit une subvention de 825 000 $ pour développer son test de biopsie liquide pour le dépistage du cancer du poumon
Vancouver, British Columbia--(Newsfile Corp. - 1 juin 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) («BioMark») est heureuse d'annoncer aujourd'hui que sa filiale en propriété exclusive BioMark Diagnostic Solutions Inc. ("BDS") a reçu un financement pour le développement d'un test de dépistage du cancer du poumon à un stade précoce en utilisant la technologie de biopsie liquide exclusive de BioMark. Le montant global de la subvention s'élève à environ 825 000$ et la...
2021-06-01 8:30 AM EDT
BioMark Announces Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announces that it has changed its auditors from Manning Elliott LLP ("Former Auditor") to PricewaterhouseCoopers LLP ("Successor Auditor"). The Former Auditor resigned as the auditor of the Company effective May 17th, 2021 and the board of directors of the Company appointed the Successor Auditor effective as of the same date, until the next Annual General...
2021-05-31 8:30 AM EDT
Biomark to Open a Diagnostic Laboratory in Quebec
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") will be operating a diagnostic laboratory in Quebec, Canada, which will primarily serve to advance the clinical validation of its proprietary liquid biopsy platform for early lung cancer detection, monitoring and predicting response to treatment. The...
2021-04-29 8:30 AM EDT
BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today the agreement by several long-time strategic accredited investors and insiders to exercise approximately 2,000,000 warrants issued in connection with the Company's private placement of units completed in April 2019, with the warrant exercise price of $0.20 per share. All the warrants were exercised before the warranty...
2021-04-21 8:30 AM EDT
Biomark's Collaborator Receives Funding to Validate Its Biomarker Panel for the Early Detection of Lung Cancer
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its sponsored research collaboration with The Metabolomics Innovation Centre (TMIC) was successful in receiving funding from the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian...
2021-03-16 8:30 AM EDT
BioMark Grants Options
Vancouver, British Columbia--(Newsfile Corp. - March 2, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that it has granted 2,100,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to third-party consultants to support market communication and corporate strategy as it advances its commercialization efforts. Each option is exercisable into one common share at a price of $0.25 per share and will vest...
2021-03-02 8:30 AM EST
BioMark and Phytronix Technologies Inc. Enter into a Collaborative Research and Development Agreement
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. has entered into a collaborative research and development agreement with Phytronix Technologies Inc. ("Phytronix") to advance the development of BioMark's early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD)...
2021-02-16 8:30 AM EST
BioMark Diagnostics Targets Response to Treatment Application with Its Liquid Biopsy Platform
Vancouver, British Columbia--(Newsfile Corp. - February 8, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that the article "Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer - a Pilot Study" has been published in the peer-reviewed journal Future Science OA. Rashid A. Bux, President and CEO of BioMark, says, "This publication shows the potential of our liquid biopsy platform's ability to provide a novel...
2021-02-08 8:30 AM EST
Alfred Berkeley Joins BioMark's Advisory Team
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark") is glad to announce Alfred Berkeley as a new member of the BioMark's Advisory team, as he will be providing strategic and financial advice to help expand the company's commercialization effort in the U.S. Mr. Rashid Ahmed Bux, CEO and President of BioMark Diagnostics says: "We are extremely proud and honored to have Mr. Berkeley join our advisory group...
2021-01-11 8:30 AM EST
BioMark Retains Questrade, Inc. to Provide Market-Making Services
Vancouver, British Columbia--(Newsfile Corp. - December 7, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that it has retained Questrade, Inc. ("Questrade") to provide market-making services in accordance with CSE guidelines. The term of the agreement is for one year, beginning December 7, 2020 at a cost of CAD $3,000 per month. Either party may terminate the agreement with 30 days written notice. Though BioMark and Questrade are unrelated...
2020-12-07 8:30 AM EST
BioMark Scientific Advisor Dr. Donald Miller to Present at the Delaware Valley Drug Metabolism Discussion Group
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that on September 29, its strategic scientific advisor Dr. Donald Miller is to present on BioMark's SSAT amantadine assay for the early detection of cancer at the prestigious Delaware Valley Drug Metabolism Discussion Group (DVDMDG). Rashid Ahmed, President and CEO of BioMark, says, "We are pleased to have Dr. Donald Miller...
2020-09-23 8:30 AM EDT
BioMark Appoints Dr. Jean-Francois Haince as Strategic Advisor to Guide Its Expansion into Quebec
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that it has appointed Dr. Jean-Francois (Jeff) Haince as a strategic advisor to its management team. Rashid Ahmed, President and CEO, says, "We are delighted to welcome Dr. Haince into our advisory team. Jeff brings a pragmatic perspective to our bench strength along with a thorough understanding of engaging within the vibrant...
2020-09-16 8:30 AM EDT
BioMark Team Invited for Full Application for Sparks Grant Competition
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that 2 of its most recent abstract submissions for the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition have resulted in invitations to submit full applications for funding. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of...
2020-09-14 8:30 AM EDT
BioMark Team Secures Health Canada Letter of No Objection for Its Glioblastoma Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA. The company would like to thank Dr. Marshall Pitz the principal investigator and is the Section Head of Clinical Research...
2020-08-27 8:30 AM EDT
BioMark Diagnostics Expands Research Development in Quebec
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions announced today that the Company is moving parts of its lung cancer research and development operations to LE CAMP, an incubator-accelerator dedicated to tech businesses growth and mentorship. "This move highlights BioMark's focus on diagnostic development and technological...
2020-08-13 8:30 AM EDT